Emerging Anti-Inflammatory COPD Treatments: Potential Cardiovascular Impacts.

107 Tezepelumab, a first-in-class human IgG 2/λ mAb that binds to TSLP and inhibits its interaction with the TSLP receptor complex, has recently been documented to result in a nominally significant reduction of 37% in the rate of moderate or severe AECOPDs in comparison to placebo. 44 In patients with a blood eosinophil count of 300 cells/μL or greater, tezepelumab resulted in a statistically significant reduction of 46% in the incidence of moderate or severe AECOPDs.

also in 7,732 other papers